PEX16 Antibody

Here’s a structured FAQ for researchers working with PEX16 antibodies, informed by technical specifications, validation data, and recent mechanistic studies:

How do I validate PEX16 antibody specificity in mammalian cell models?

• Methodological approach:

  • Use positive controls such as HepG2 cells (validated for PEX16 detection in WB/IF ).

  • Compare observed vs. calculated molecular weights (38 kDa vs. 39 kDa) via Western blot .

  • Perform siRNA knockdown or CRISPR KO in target cell lines (e.g., HeLa) and confirm loss of signal .

  • Validate cross-reactivity using lysates from cited species (human, mouse, rat) .

What experimental conditions optimize PEX16 detection across applications?

How to address discrepancies in observed vs. predicted PEX16 molecular weight?

• The 38 kDa observed mass (vs. 39 kDa calculated) may arise from:

  • Post-translational modifications (e.g., phosphorylation) .

  • Alternative splicing isoforms (check cell-type-specific expression) .

  • Confirm using multiple antibodies (e.g., compare polyclonal 14816-1-AP and monoclonal 68261-1-Ig results) .

How does PEX16 antibody selection impact studies of peroxisome biogenesis mechanisms?

• Polyclonal vs. monoclonal trade-offs:

  Parameter	Polyclonal (14816-1-AP)	Monoclonal (68261-1-Ig)
  Epitope coverage	Broad (fusion protein Ag6566)	Single epitope (Ag6574)
  KO validation	Compatible	Untested in KO models
  Multiplexing	May cross-react with arabidopsis	Human/rat/mouse-specific

• Critical application: Use polyclonal for de novo peroxisome formation assays (validated in PEX16-KO rescue ).

How to resolve contradictory findings in PEX16 knockout phenotypes?

• Key variables:

  • Cell type: HeLa PEX16-KO shows heterogeneous peroxisome loss vs. GM06231 fibroblasts (complete loss) .

  • Assay timeline: Peroxisome reformation occurs slowly in KO models (1–2 weeks post-transfection) .

  • Protocol recommendation:

    • Use dual-labeling (PMP70 + catalase) to distinguish membrane/matrix defects .

    • Combine immunoblotting (PEX16 absence) with EM for ultrastructural analysis.

What controls are essential when studying PEX16-ER interactions?

• Include:

  • Sec16B siRNA (impairs ER-to-peroxisome trafficking ).

  • Brefeldin A treatment to disrupt ER-Golgi transport .

  • Co-stain with ER markers (e.g., calnexin) and peroxisomal markers (PMP70) .

High background in immunofluorescence – how to mitigate?

• Optimization steps:

  • Reduce primary antibody concentration to 1:50 .

  • Include 0.1% saponin in blocking buffer to permeabilize membranes.

  • Validate with PEX16-KO cells to confirm signal specificity .

How to validate antibody performance in novel species (e.g., zebrafish)?

• Workflow:

  • Perform sequence alignment (human PEX16 vs. target species).

  • Test antibody in overexpression systems (e.g., transient transfection).

  • Compare with RNAi-mediated knockdown (morpholinos/CRISPR) .